bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
bioAffinity Technologies (Nasdaq: BIAF) has appointed Dr. William Bauta as Chief Science Officer, succeeding Dr. Vivienne Rebel who retired on Oct. 31, 2024. Dr. Bauta, previously Senior VP of Research and Development since 2016, brings experience from Genzyme and Ilex Products. He has contributed to multiple company inventions and patents, particularly in optimizing CyPath® Lung, their noninvasive early-stage lung cancer detection test. His work has improved test performance, reduced costs, and expanded the company's patent portfolio. Dr. Bauta earned his Ph.D. from the University of Chicago and completed post-doctoral studies at the University of Texas at Austin.
bioAffinity Technologies (Nasdaq: BIAF) ha nominato il Dr. William Bauta come Chief Science Officer, succedendo al Dr. Vivienne Rebel che si è ritirato il 31 ottobre 2024. Il Dr. Bauta, precedentemente Vicepresidente Senior di Ricerca e Sviluppo dal 2016, porta con sé un'esperienza maturata in Genzyme e Ilex Products. Ha contribuito a molteplici invenzioni e brevetti aziendali, in particolare nell'ottimizzazione del CyPath® Lung, il loro test non invasivo per la rilevazione precoce del cancro ai polmoni. Il suo lavoro ha migliorato le prestazioni del test, ridotto i costi e ampliato il portafoglio brevetti della compagnia. Il Dr. Bauta ha ottenuto il dottorato presso l'Università di Chicago e ha completato studi post-dottorali all'Università del Texas ad Austin.
bioAffinity Technologies (Nasdaq: BIAF) ha nombrado al Dr. William Bauta como Director Científico, sucediendo a la Dra. Vivienne Rebel, quien se retiró el 31 de octubre de 2024. El Dr. Bauta, que anteriormente fue Vicepresidente Senior de Investigación y Desarrollo desde 2016, aporta experiencia de Genzyme e Ilex Products. Ha contribuido a múltiples invenciones y patentes de la empresa, especialmente en la optimización del CyPath® Lung, su prueba no invasiva para la detección temprana del cáncer de pulmón. Su trabajo ha mejorado el rendimiento de la prueba, reducido costos y expandido el portafolio de patentes de la compañía. El Dr. Bauta obtuvo su doctorado en la Universidad de Chicago y completó estudios postdoctorales en la Universidad de Texas en Austin.
bioAffinity Technologies (Nasdaq: BIAF)는 Dr. William Bauta를 최고 과학 책임자로 임명하고, 2024년 10월 31일 은퇴한 Dr. Vivienne Rebel의 뒤를 잇게 되었습니다. Bauta 박사는 2016년부터 연구 및 개발의 수석 부사장으로 재직해 왔으며, Genzyme와 Ilex Products에서의 경험을 가지고 있습니다. 그는 CyPath® Lung의 최적화, 즉 비침습적인 초기 폐암 검사에 관한 여러 기업 발명 및 특허에 기여했습니다. 그의 작업은 검사 성능을 개선하고 비용을 줄이며 회사의 특허 포트폴리오를 확장하는 데 도움이 되었습니다. Bauta 박사는 시카고 대학교에서 박사 학위를 받고 텍사스 대학교 오스틴에서 박사 후 연구를 마쳤습니다.
bioAffinity Technologies (Nasdaq: BIAF) a nommé le Dr. William Bauta au poste de Directeur Scientifique, succédant à la Dr. Vivienne Rebel, qui a pris sa retraite le 31 octobre 2024. Le Dr. Bauta, anciennement Vice-Président Senior de la Recherche et du Développement depuis 2016, apporte une expérience acquise chez Genzyme et Ilex Products. Il a contribué à de nombreuses inventions et brevets de l'entreprise, en particulier à l'optimisation du CyPath® Lung, leur test non invasif de détection précoce du cancer du poumon. Son travail a amélioré les performances du test, réduit les coûts et élargi le portefeuille de brevets de l'entreprise. Le Dr. Bauta a obtenu son doctorat à l'Université de Chicago et a complété des études postdoctorales à l'Université du Texas à Austin.
bioAffinity Technologies (Nasdaq: BIAF) hat Dr. William Bauta zum Chief Science Officer ernannt, der Dr. Vivienne Rebel nachfolgt, die am 31. Oktober 2024 in den Ruhestand trat. Dr. Bauta war seit 2016 Senior VP für Forschung und Entwicklung und bringt Erfahrung von Genzyme und Ilex Products mit. Er hat zu zahlreichen Unternehmensinventionen und -patenten beigetragen, insbesondere zur Optimierung des CyPath® Lung, ihres nicht-invasiven Frühdiagnosetests für Lungenkrebs. Seine Arbeit hat die Testleistung verbessert, die Kosten gesenkt und das Patentportfolio des Unternehmens erweitert. Dr. Bauta erwarb seinen Doktortitel an der University of Chicago und absolvierte postdoktorale Studien an der University of Texas in Austin.
- Dr. Bauta's improvements to CyPath® Lung have enhanced performance while reducing costs
- Multiple company inventions and patents attributed to Dr. Bauta
- Expanded patent portfolio through new discoveries
- None.
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel
Dr. Bauta is responsible for multiple Company inventions and patents supporting bioAffinity’s diagnostic and therapeutic advancements, including improvements to optimize CyPath® Lung, the Company’s noninvasive test to detect early-stage lung cancer, that both improved performance and cut costs. His discoveries have expanded the Company’s patent portfolio and added to a growing list of publications. In addition to bioAffinity patents on which he is a named inventor, he holds multiple healthcare-related patents and has published in more than a dozen scientific journals, including the journal Science.
“Dr. Bauta brings both scientific rigor and business acumen to the CSO position as we accelerate the commercial rollout of our CyPath® Lung test and expand our development pipeline. He will work with an exceptional scientific team who developed our high throughput, automated diagnostic platform to accurately analyze the lung microenvironment, allowing us to advance new technologies that can detect early-stage diseases. He is focused on making our products important steps in the care pathway for diagnosing early-stage disease,” bioAffinity President and CEO Maria Zannes said.
Dr. Bauta earned his Ph.D. from the University of
Dr. Bauta succeeds Vivienne I. Rebel, M.D., Ph.D. who retired from her position on Oct. 31, 2024, as Executive Vice President and Chief Science and Medical Officer. Dr. Rebel joined the Company in 2016 and led the research and development of CyPath® Lung.
“We wish Dr. Rebel the very best in retirement,” said Zannes. “Vivienne has made an indelible mark on us all. Her scientific precision and innovative spirit will remain a hallmark of bioAffinity Technologies.”
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding accelerating the commercial rollout of our CyPath® Lung test, expanding our development pipeline, advancing new technologies that can detect early-stage diseases, and making our products important steps in the care pathway for diagnosing early-stage disease. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to accelerate the commercial rollout of its CyPath® Lung test, expand its development pipeline, advance new technologies that can detect early-stage diseases and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104703672/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.
FAQ
Who is the new Chief Science Officer of bioAffinity Technologies (BIAF)?
What improvements has Dr. Bauta made to CyPath® Lung at bioAffinity Technologies (BIAF)?
When did Dr. Vivienne Rebel retire from bioAffinity Technologies (BIAF)?
What is bioAffinity Technologies' (BIAF) main product focus?
